John R Toomey

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor
    Melanie A Abboud
    GlaxoSmithKline, Cardiovascular and Urogenital Diseases Center of Excellence, King of Prussia, Pennsylvania, USA
    J Cardiovasc Pharmacol 52:66-71. 2008
  2. ncbi Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke
    John R Toomey
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Stroke 33:578-85. 2002
  3. ncbi The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis
    John R Toomey
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, 709 Swedeland Road, PO Box 1539, Mail code UW 2510, King of Prussia, PA 19406, USA
    Curr Drug Targets Cardiovasc Haematol Disord 2:13-25. 2002
  4. ncbi Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides
    Chuen Chan
    CVU UK Medicinal Chemistry Department, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    J Med Chem 50:1546-57. 2007
  5. ncbi Selective and dual action orally active inhibitors of thrombin and factor Xa
    Robert J Young
    GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
    Bioorg Med Chem Lett 17:2927-30. 2007
  6. ncbi Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs
    Robert J Young
    GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    Bioorg Med Chem Lett 18:28-33. 2008
  7. ncbi Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs
    Robert J Young
    GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
    Bioorg Med Chem Lett 18:23-7. 2008
  8. ncbi Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function
    Joseph A Erhardt
    Department of Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA
    Exp Hematol 37:1030-7. 2009
  9. ncbi The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa
    Aysar Aktimur
    Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232, USA
    J Biol Chem 278:7981-7. 2003

Collaborators

Detail Information

Publications9

  1. ncbi Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor
    Melanie A Abboud
    GlaxoSmithKline, Cardiovascular and Urogenital Diseases Center of Excellence, King of Prussia, Pennsylvania, USA
    J Cardiovasc Pharmacol 52:66-71. 2008
    ....
  2. ncbi Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke
    John R Toomey
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Stroke 33:578-85. 2002
    ..In this study, using a rat thromboembolic stroke model, we investigated the use of an inhibitory anti-factor IX(a) monoclonal antibody (SB 249417) for the treatment of thromboembolic stroke and compared its efficacy to that of tPA...
  3. ncbi The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis
    John R Toomey
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, 709 Swedeland Road, PO Box 1539, Mail code UW 2510, King of Prussia, PA 19406, USA
    Curr Drug Targets Cardiovasc Haematol Disord 2:13-25. 2002
    ..However, the combined evidence suggests that these acute canine thrombosis studies may not completely capture the pathology reflected in chronic human atherothrombotic disease...
  4. ncbi Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides
    Chuen Chan
    CVU UK Medicinal Chemistry Department, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    J Med Chem 50:1546-57. 2007
    ..Pharmacokinetic profiles in rat and dog, together with selectivity over other trypsin-like serine proteases, identified 1f as a candidate for further evaluation...
  5. ncbi Selective and dual action orally active inhibitors of thrombin and factor Xa
    Robert J Young
    GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
    Bioorg Med Chem Lett 17:2927-30. 2007
    ....
  6. ncbi Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs
    Robert J Young
    GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
    Bioorg Med Chem Lett 18:28-33. 2008
    ....
  7. ncbi Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs
    Robert J Young
    GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
    Bioorg Med Chem Lett 18:23-7. 2008
    ....
  8. ncbi Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function
    Joseph A Erhardt
    Department of Oncology, GlaxoSmithKline, Collegeville, PA 19426, USA
    Exp Hematol 37:1030-7. 2009
    ..In addition to effects on megakaryocytes, TPOR stimulation also impacts platelet function. The present study examined platelet function following stimulation with the small molecule TPOR agonist eltrombopag...
  9. ncbi The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa
    Aysar Aktimur
    Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232, USA
    J Biol Chem 278:7981-7. 2003
    ..The data demonstrate that factor XIa binds with comparable affinity to factors IX and IXabeta and that the interactions are dependent on the factor IX Gla domain...